 | • レポートコード：MRC2304I0189 • 出版社/出版日：Persistence Market Research / 2023年1月30日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,124,800 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,568,800 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料では、世界の膣用抗真菌薬市場について調査・分析を行い、市場の現状と今後の展望を整理しています。本書は、エグゼクティブサマリー、市場概要、主要市場動向、主要成功要因、市場背景、新型コロナウイルス感染症危機分析、需要分析・予測、治療薬別（フルコナゾール、ナイスタチン、フルシトシン、クロトリマゾール、その他）分析、投与経路別（経口、局所）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、中南米、ヨーロッパ、東アジア、南アジア、オセアニア、中東・アフリカ）分析、市場構造分析、競争分析、仮定、調査手法など、以下の構成で掲載しています。また、Pfizer Inc.、Bausch Health Companies Inc、ANI Pharmaceuticals, Inc.、Hikma Pharmaceuticals Plc、Lupin Limited、Mycovia Pharmaceuticals, Inc.、Glenmark Pharmaceuticals Limited、Unique Pharmaceuticals、PEPTONIC medical AB、Aurobindo Pharma Limited、Dr. Reddy's Laboratories、SCYNEXIS, Inc.、Basilea Pharmaceutica Ltd.、Astellas Pharma Inc.などの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・主要市場動向 ・主要成功要因 ・市場背景 ・新型コロナウイルス感染症危機分析 ・需要分析・予測 ・世界の膣用抗真菌薬市場規模：治療薬別 - フルコナゾールの市場規模 - ナイスタチンの市場規模 - フルシトシンの市場規模 - クロトリマゾールの市場規模 - その他治療薬の市場規模 ・世界の膣用抗真菌薬市場規模：投与経路別 - 経口投与における市場規模 - 局所投与における市場規模 ・世界の膣用抗真菌薬市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 ・世界の膣用抗真菌薬市場規模：地域別 - 北米の膣用抗真菌薬市場規模 - 中南米の膣用抗真菌薬市場規模 - ヨーロッパの膣用抗真菌薬市場規模 - 東アジアの膣用抗真菌薬市場規模 - 南アジアの膣用抗真菌薬市場規模 - オセアニアの膣用抗真菌薬市場規模 - 中東・アフリカの膣用抗真菌薬市場規模 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Vaginal Antifungals Market – Report Scope
A recent market study published by Persistence Market Research on the vaginal antifungals market offers a global industry analysis for 2017 to 2021 and an opportunity assessment for 2022 to 2032. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the vaginal antifungals market, growth prospects of the market are obtained with maximum precision.
The report features unique and salient factors that may make a huge impact on the development of the vaginal antifungals market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.
The report provides detailed information about the current and future growth prospects of the vaginal antifungals market in the most comprehensive way for a better understanding of readers.
Key Market Segments
The study on the vaginal antifungals market offers insights divided into four important segments – drug, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.
Drug
Fluconazole
Nystatin
Flucytosine
Clotrimazole
Ketoconazole
Terbinafine
Others
Route of Administration
Oral
Topical
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Region
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa
Chapter 1 – Executive Summary
The report commences with the executive summary of the vaginal antifungals market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the vaginal antifungals market as well as the key trends influencing the market.
Chapter 2 – Market Overview
Readers can find detailed taxonomy and drug definition/scope /limitations and inclusions and exclusions of the vaginal antifungals market in this chapter, which helps the readers to understand basic information about the vaginal antifungals market.
Chapter 3 – Key Market Trends
This section highlights the key trends influencing the vaginal antifungals market, which will help readers in understanding the current trends and their impact on market growth.
Chapter 4 – Key Success Factors
This section highlights the market context impacting the vaginal antifungals market, which will help readers in understanding promotional strategies, by key manufacturers, key regulations, reimbursement scenario, pipeline analysis, value chain analysis, PESTEL analysis, and Porter’s analysis, that are expected to create a positive impact on the growth of the vaginal antifungals market during the forecast period.
Chapter 5- Market Background
This chapter explains the key macroeconomic factors that are expected to influence the growth of the vaginal antifungals market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the vaginal antifungals market, which include the drivers, restraints, and opportunity analysis.
Chapter 6 – COVID-19 Crisis Analysis
This section provides the current and expected impact of COVID-19 on the vaginal antifungals market.
Chapter 7- Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032
This section explains the global market value or size analysis and forecasts for the vaginal antifungals market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2022), and an incremental $ opportunity for the forecast period (2022–2032).
Chapter 8- Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, by Drug
Based on the drug, the vaginal antifungals market is segmented into Fluconazole, Nystatin, Flucytosine, Clotrimazole, Ketoconazole, Terbinafine, and others. In this chapter, readers can find information about a detailed analysis of the market by different drugs available in the vaginal antifungals market and their growth over the forecast period.
Chapter 9- Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
Based on the route of administration, the vaginal antifungals market is segmented into oral, and topical. In this chapter, readers can find information about a detailed analysis of the market by various routes of administration available in the vaginal antifungals market and their growth over the forecast period.
Chapter 10– Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
Based on the distribution channel, the vaginal antifungals market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In this chapter, readers can find information about a detailed analysis of the market by distribution channels available in the vaginal antifungals market and their growth over the forecast period.
Chapter 11 – Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032, by Region
This chapter explains how the vaginal antifungals market will grow across seven geographic regions, North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East and Africa (MEA).
Chapter 12- North America Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes a detailed analysis of the growth of the North American vaginal antifungals market along with a country-wise assessment including the U.S. and Canada. Readers can also find key takeaways of this region, and market growth based on drug, distribution channel, route of administration, and country of the vaginal antifungals market in the North American region.
Chapter 13- Latin America Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes the growth prospects of the vaginal antifungals market in leading countries such as Brazil, Mexico, Argentina, and the rest of Latin America. Readers can find thorough information about the growth parameters based on drug, distribution channel, route of administration, and country in the Latin America vaginal antifungals market during 2022-2032.
Chapter 14- Europe Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
This chapter includes the growth prospects of the vaginal antifungals market based on the development of the new product, regulatory approvals, and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, BENELUX, and the Rest of Europe are included in this chapter.
Chapter 15- East Asia Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
China, Japan, and South Korea are the prime subjects of assessment to obtain the growth prospects of the East Asia vaginal antifungals market. In addition, in this chapter, readers can find thorough information about the growth parameters of the East Asia vaginal antifungals market through 2032.
Chapter 16- South Asia Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
India, Thailand, Indonesia, Malaysia, and the rest of South Asia are the prime subjects of assessment to obtain the growth prospects of the vaginal antifungals market. In addition, in this chapter, readers can find thorough information about the growth parameters of the South Asia vaginal antifungals market growth over the forecast period.
Chapter 17- Oceania Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
This chapter consists of important parameters that have a huge impact on the growth of the vaginal antifungals market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania vaginal antifungals market.
Chapter 18- Middle East and Africa Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022-2032
This chapter provides information on how the vaginal antifungals market will grow in the major countries in the MEA region, such as GCC Countries, Türkiye, and the rest of MEA during 2022-2032.
Chapter 19- Market Structure Analysis
This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key players operating in the vaginal antifungals market.
Chapter 20- Competition Analysis
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the vaginal antifungals market including company overview, revenue shares, strategic overview, and recent company developments. Some of the major market players featured in the report are Pfizer Inc., Bausch Health Companies Inc, ANI Pharmaceuticals, Inc., Hikma Pharmaceuticals Plc, Lupin Limited, Mycovia Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Unique Pharmaceuticals, PEPTONIC Medical AB, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories, SCYNEXIS, Inc., Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., and Amplyx Pharmaceuticals Inc.
Chapter 21 – Assumptions and Acronyms Used
This chapter includes a list of acronyms and assumptions that provide a base for the information and statistics included in the report.
Chapter 22 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about the vaginal antifungals market.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Key Innovation / Development Trends
4. Key Success Factors
4.1. Promotional Strategies, By Key Manufacturers
4.2. Key Regulations
4.3. Reimbursement Scenario
4.4. Pipeline Analysis
4.5. Value Chain Analysis
4.6. PESTEL Analysis
4.7. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Antifungal Drugs Market Outlook
5.2. Forecast Factors – Relevance & Impact
5.2.1. Impact of the COVID-19 Pandemic
5.2.2. Increasing Product Launch Activities
5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
5.2.4. High Rates of Vulvovaginal Candidiasis
5.2.5. Impact on Quality-of-Life
5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
5.2.7. Growing Problems of Azole Resistance
5.2.8. Toxicity of Antifungal Drugs
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Drug
6.1.2. By Route of Administration
6.1.3. By Distribution Channel
6.1.4. By Country
6.2. 2021 Market Scenario
7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022–2032, By Drug
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2017 – 2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2022 – 2032
8.3.1. Fluconazole
8.3.2. Nystatin
8.3.3. Flucytosine
8.3.4. Clotrimazole
8.3.5. Ketoconazole
8.3.6. Terbinafine
8.3.7. Others
8.4. Market Attractiveness Analysis By Drug
9. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022–2032, By Route of Administration
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2017 – 2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022 – 2032
9.3.1. Oral
9.3.2. Topical
9.4. Market Attractiveness Analysis By Route of Administration
10. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022–2032, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017 – 2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2022 – 2032
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis By Distribution Channel
11. Global Vaginal Antifungals Market Analysis 2017-2021 and Forecast 2022–2032, By Region
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region
12. North America Vaginal Antifungals Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
12.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Drug
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug
12.4.3. By Route of Administration
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants – Intensity Mapping
12.7. Drivers and Restraints – Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Vaginal Antifungals Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast By Market Taxonomy
12.8.1.2.1. By Drug
12.8.1.2.2. By Route of Administration
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Vaginal Antifungals Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast By Market Taxonomy
12.8.2.2.1. By Drug
12.8.2.2.2. By Route of Administration
12.8.2.2.3. By Distribution Channel
13. Latin America Vaginal Antifungals Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
13.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.1.4.1. By Country
13.3.1.4.2. By Drug
13.3.1.4.3. By Route of Administration
13.3.1.4.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug
13.4.3. By Route of Administration
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints – Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Vaginal Antifungals Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast By Market Taxonomy
13.8.1.2.1. By Drug
13.8.1.2.2. By Route of Administration
13.8.1.2.3. By Distribution Channel
13.8.2. Brazil Vaginal Antifungals Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast By Market Taxonomy
13.8.2.2.1. By Country
13.8.2.2.2. By Drug
13.8.2.2.3. By Route of Administration
13.8.2.2.4. By Distribution Channel
13.8.3. Argentina Vaginal Antifungals Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast By Market Taxonomy
13.8.3.2.1. By Drug
13.8.3.2.2. By Route of Administration
13.8.3.2.3. By Distribution Channel
14. Europe Vaginal Antifungals Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
14.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Drug
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug
14.4.3. By Route of Administration
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints – Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Vaginal Antifungals Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast By Market Taxonomy
14.8.1.2.1. By Drug
14.8.1.2.2. By Route of Administration
14.8.1.2.3. By Distribution Channel
14.8.2. Italy Vaginal Antifungals Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast By Market Taxonomy
14.8.2.2.1. By Drug
14.8.2.2.2. By Route of Administration
14.8.2.2.3. By Distribution Channel
14.8.3. France Vaginal Antifungals Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast By Market Taxonomy
14.8.3.2.1. By Drug
14.8.3.2.2. By Route of Administration
14.8.3.2.3. By Distribution Channel
14.8.4. U.K. Vaginal Antifungals Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast By Market Taxonomy
14.8.4.2.1. By Drug
14.8.4.2.2. By Route of Administration
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Vaginal Antifungals Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast By Market Taxonomy
14.8.5.2.1. By Drug
14.8.5.2.2. By Route of Administration
14.8.5.2.3. By Distribution Channel
14.8.6. BENELUX Vaginal Antifungals Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast By Market Taxonomy
14.8.6.2.1. By Drug
14.8.6.2.2. By Route of Administration
14.8.6.2.3. By Distribution Channel
14.8.7. Russia Vaginal Antifungals Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast By Market Taxonomy
14.8.7.2.1. By Drug
14.8.7.2.2. By Route of Administration
14.8.7.2.3. By Distribution Channel
15. East Asia Vaginal Antifungals Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
15.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug
15.3.3. By Route of Administration
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug
15.4.3. By Route of Administration
15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints – Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Vaginal Antifungals Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast By Market Taxonomy
15.8.1.2.1. By Drug
15.8.1.2.2. By Route of Administration
15.8.1.2.3. By Distribution Channel
15.8.2. Japan Vaginal Antifungals Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast By Market Taxonomy
15.8.2.2.1. By Drug
15.8.2.2.2. By Route of Administration
15.8.2.2.3. By Distribution Channel
15.8.3. South Korea Vaginal Antifungals Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast By Market Taxonomy
15.8.3.2.1. By Drug
15.8.3.2.2. By Route of Administration
15.8.3.2.3. By Distribution Channel
16. South Asia Vaginal Antifungals Market Analysis 2017–2021 and Forecast 2022–2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
16.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Drug
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug
16.4.3. By Route of Administration
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints – Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Vaginal Antifungals Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast By Market Taxonomy
16.8.1.2.1. By Drug
16.8.1.2.2. By Route of Administration
16.8.1.2.3. By Distribution Channel
16.8.2. Indonesia Vaginal Antifungals Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast By Market Taxonomy
16.8.2.2.1. By Drug
16.8.2.2.2. By Route of Administration
16.8.2.2.3. By Distribution Channel
16.8.3. Malaysia Vaginal Antifungals Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast By Market Taxonomy
16.8.3.2.1. By Drug
16.8.3.2.2. By Route of Administration
16.8.3.2.3. By Distribution Channel
16.8.4. Thailand Vaginal Antifungals Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast By Market Taxonomy
16.8.4.2.1. By Drug
16.8.4.2.2. By Route of Administration
16.8.4.2.3. By Distribution Channel
17. Oceania Vaginal Antifungals Market 2017-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
17.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Drug
17.3.3. By Route of Administration
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug
17.4.3. By Route of Administration
17.4.4. By Distribution Channel
17.5. Key Market Participants – Intensity Mapping
17.6. Drivers and Restraints – Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. Australia Vaginal Antifungals Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast By Market Taxonomy
17.7.1.2.1. By Drug
17.7.1.2.2. By Route of Administration
17.7.1.2.3. By Distribution Channel
17.7.2. New Zealand Vaginal Antifungals Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast By Market Taxonomy
17.7.2.2.1. By Drug
17.7.2.2.2. By Route of Administration
17.7.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2017–2021 and Forecast 2022–2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2017–2021
18.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2022–2032
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. North Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Drug
18.3.3. By Route of Administration
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug
18.4.3. By Route of Administration
18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants – Intensity Mapping
18.7. Drivers and Restraints – Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Vaginal Antifungals Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast By Market Taxonomy
18.8.1.2.1. By Drug
18.8.1.2.2. By Route of Administration
18.8.1.2.3. By Distribution Channel
18.8.2. Türkiye Vaginal Antifungals Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast By Market Taxonomy
18.8.2.2.1. By Drug
18.8.2.2.2. By Route of Administration
18.8.2.2.3. By Distribution Channel
18.8.3. South Africa Vaginal Antifungals Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast By Market Taxonomy
18.8.3.2.1. By Drug
18.8.3.2.2. By Route of Administration
18.8.3.2.3. By Distribution Channel
18.8.4. North Africa Vaginal Antifungals Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast By Market Taxonomy
18.8.4.2.1. By Drug
18.8.4.2.2. By Route of Administration
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis By Tier of Companies
19.2. Market Concentration
19.3. Market Share Analysis of Top Players
19.4. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Pfizer Inc.
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Sales Footprint
20.3.1.4. Key Financials
20.3.1.5. SWOT Analysis
20.3.1.6. Strategic Overview
20.3.2. Bausch Health Companies Inc
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Sales Footprint
20.3.2.4. Key Financials
20.3.2.5. SWOT Analysis
20.3.2.6. Strategic Overview
20.3.3. ANI Pharmaceuticals, Inc.
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Sales Footprint
20.3.3.4. Key Financials
20.3.3.5. SWOT Analysis
20.3.3.6. Strategic Overview
20.3.4. Hikma Pharmaceuticals Plc
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Sales Footprint
20.3.4.4. Key Financials
20.3.4.5. SWOT Analysis
20.3.4.6. Strategic Overview
20.3.5. Lupin Limited
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Sales Footprint
20.3.5.4. Key Financials
20.3.5.5. SWOT Analysis
20.3.5.6. Strategic Overview
20.3.6. Mycovia Pharmaceuticals, Inc.
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Sales Footprint
20.3.6.4. Key Financials
20.3.6.5. SWOT Analysis
20.3.6.6. Strategic Overview
20.3.7. Glenmark Pharmaceuticals Limited
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Sales Footprint
20.3.7.4. Key Financials
20.3.7.5. SWOT Analysis
20.3.7.6. Strategic Overview
20.3.8. Unique Pharmaceuticals
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Sales Footprint
20.3.8.4. Key Financials
20.3.8.5. SWOT Analysis
20.3.8.6. Strategic Overview
20.3.9. PEPTONIC medical AB
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Sales Footprint
20.3.9.4. Key Financials
20.3.9.5. SWOT Analysis
20.3.9.6. Strategic Overview
20.3.10. Aurobindo Pharma Limited
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Sales Footprint
20.3.10.4. Key Financials
20.3.10.5. SWOT Analysis
20.3.10.6. Strategic Overview
20.3.11. Dr. Reddy’s Laboratories
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Sales Footprint
20.3.11.4. Key Financials
20.3.11.5. SWOT Analysis
20.3.11.6. Strategic Overview
20.3.12. SCYNEXIS, Inc.
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Sales Footprint
20.3.12.4. Key Financials
20.3.12.5. SWOT Analysis
20.3.12.6. Strategic Overview
20.3.13. Basilea Pharmaceutica Ltd.
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Sales Footprint
20.3.13.4. Key Financials
20.3.13.5. SWOT Analysis
20.3.13.6. Strategic Overview
20.3.14. Astellas Pharma Inc.
20.3.14.1. Overview
20.3.14.2. Product Portfolio
20.3.14.3. Sales Footprint
20.3.14.4. Key Financials
20.3.14.5. SWOT Analysis
20.3.14.6. Strategic Overview
20.3.15. Grupo Ferrer Internacional, S.A.
20.3.15.1. Overview
20.3.15.2. Product Portfolio
20.3.15.3. Sales Footprint
20.3.15.4. Key Financials
20.3.15.5. SWOT Analysis
20.3.15.6. Strategic Overview
20.3.16. Pacgen Life Science Corporation
20.3.16.1. Overview
20.3.16.2. Product Portfolio
20.3.16.3. Sales Footprint
20.3.16.4. Key Financials
20.3.16.5. SWOT Analysis
20.3.16.6. Strategic Overview
20.3.17. NovaDigm Therapeutics, Inc.
20.3.17.1. Overview
20.3.17.2. Product Portfolio
20.3.17.3. Sales Footprint
20.3.17.4. Key Financials
20.3.17.5. SWOT Analysis
20.3.17.6. Strategic Overview
20.3.18. Cidara Therapeutics, Inc.
20.3.18.1. Overview
20.3.18.2. Product Portfolio
20.3.18.3. Sales Footprint
20.3.18.4. Key Financials
20.3.18.5. SWOT Analysis
20.3.18.6. Strategic Overview
20.3.19. Amplyx Pharmaceuticals Inc.
20.3.19.1. Overview
20.3.19.2. Product Portfolio
20.3.19.3. Sales Footprint
20.3.19.4. Key Financials
20.3.19.5. SWOT Analysis
20.3.19.6. Strategic Overview
21. Assumptions and Acronyms Used
22. Research Methodology